• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Start-Up Stadium Tuesday Morning

Tuesday, June 04, 2024
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2024 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback. This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the Illumina Accelerator and The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of BIO Business Solutions.
Loading
11:00 AM – 1:00 PM
(PST)
  1. We are addressing the need for tissue repair solutions, beginning with cornea.
    SUS
    • Ophthalmology
  2. Black Canyon Bio (BCB) is developing novel products for treating cancer using our proprietary Specific Neo-Antigen Peptides (SNAPTM) Technology platform.
    SUS
    • Oncology
  3. FELIQS is a clinical-ready stage company. The Company has a portfolio of two patent-protected drug product ophthalmology candidates.
    SUS
    • Ophthalmology
  4. Jaan biotherapeutics is a pre-investigational new drug application company developing treatments that target microRNAs to regenerate heart muscle withing the heart and treat heart disease, the largest cause of death of man.
    SUS
    • Cardiovascular
  5. Mabswitch Inc, is a leading biotechnology firm specializing in the development of regulatable immunotherapies based on the groundbreaking invention of affinity switches for antibodies.
    SUS
    • Oncology
  6. Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development.
    SUS
    • Oncology
  7. SLAM Bio is a preclinical stage biotech company developing a platform of antibodies and antibody drug conjugates (ADCs) against signaling lymphocytic activation molecule (SLAM) protein family.
    SUS
    • Oncology
2:00 PM – 4:00 PM
(PST)
  1. KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage.
    SUS
    • Cardiovascular
11:00 AM – 1:00 PM
(PST)
  1. CELLeBRAIN is an R&D biotechnology company specializing in the development of gene and cell therapy for the treatment of solid cancers, with a particular focus on glioblastoma multiforme (GBM).
    SUS
    • Oncology


 
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS